Product Description
Mechanisms of Action: Btk Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Agilent Technologies
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Lupus Erythematosus, Systemic|Healthy Volunteers|Autoimmune Disease Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03878303 |
AC00582017-101 | P1 |
Unknown status |
Lupus Erythematosus, Systemic |
2020-12-01 |
21% |
2021-12-03 |
Primary Endpoints|Treatments|Trial Status |
NCT02847325 |
AC00582015-101 | P1 |
Completed |
Healthy Volunteers|Autoimmune Disease Unspecified |
2017-04-01 |
2019-03-22 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/05/2021 |
News Article |
Sorrento Enters Into Merger Agreement to Acquire Late-Stage Oncology Company ACEA Therapeutics |